Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser before eye implant may prevent glaucoma damage

NCT ID NCT04232982

Disease control Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a laser treatment (transscleral cyclophotocoagulation) to lower eye pressure before a Boston keratoprosthesis (a plastic cornea implant) can prevent or slow glaucoma. Twenty adults who need the implant will receive one of two laser types 4-8 weeks before surgery and be followed for up to 5 years. The goal is to see if this approach reduces glaucoma progression and the need for additional treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Dec 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults patients * Able to give an informed consent * Capable of being followed during the study * Candidate for the Boston keratoprosthesis type I Exclusion Criteria: * Patients younger than 18 years old or older than 80 years old * Unable to give an informed consent * Participating to another interventional glaucoma study * Patients who received a glaucoma surgery or procedure (glaucoma drainage device or TS-CPC treatment) 3 months before their initial visit. * Unable to wear a therapeutic contact lens secondary to eyelid malformation * Severe Ocular surface Disease with keratinization * Intra-ocular tumor * Terminal Glaucoma * Phthisis bulbi * Ocular albinism

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cornea disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal disorder eye disorder glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cornea disease Eye diseases Glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier de l'Université de Montréal (CHUM)

    RECRUITING

    Montreal, Quebec, H2X 3E4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.